Ditch Viking Therapeutics. Here’s a weight-loss stock to watch
Investors in search of a weight-loss play should look beyond underperforming Viking Therapeutics. Enterar Therapeutics (ENTX) is a promising contender with a differentiated approach. Their investigational drug, Entereg, targets a key hormone involved in appetite regulation, opening up a potentially lucrative market.
Enterar’s focus on neuroendocrine control sets it apart from traditional weight-loss therapies. With positive Phase 2b data and a Phase 3 trial underway, Enterar has significant catalysts ahead. Analysts are bullish, with a consensus price target of $25, representing a substantial upside.
While Viking Therapeutics has faced setbacks, Enterar Therapeutics presents a more compelling opportunity for investors seeking exposure to the burgeoning weight-loss market. Its unique mechanism of action, promising clinical data, and favorable analyst sentiment make it a stock to watch.